Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company submitted a new drug marketing application to the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the indications of telicibizumab injection (GR1802 injection) for moderate and severe atopic dermatitis in adults and was accepted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.